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 Predicting an allograft ’ s fate 
 Thomas  Fehr 1 and  Clemens D.  Cohen 1 , 2  
 Renal allografts inevitably develop progressive morphological and 
functional deterioration. Naesens  et al. now report on a transcriptomic 
approach to identify transcriptional markers that might predict rapid 
development of chronic damage even in histologically unremarkable 
allografts. The data indicate that processes similar to those seen in overt 
acute rejection are also involved in chronic allograft nephropathy. 
Identifying such  ‘ sub-morphological ’ markers should help us to better 
understand biological processes leading to chronic allograft failure. 
 Kidney International (2011)  80, 1254 – 1255;  doi: 10.1038/ki.2011.328 
 Destiny — our cultural heritage is rich in 
stories telling about humans who struggle 
with the foreseen and attempt to change 
their fate. Greek legends, Shakespeare ’ s 
drama, and even modern science fi ction 
movies deal with the dilemma of being 
unable to outmaneuver the prediction. Cur-
rently, we are experiencing an era of  ‘ predic-
tive medicine. ’ Modern techniques have 
been successful in predicting the outcome 
of disease for specifi c cohorts. In parallel, 
they help to focus on candidate molecules 
and biological processes centrally involved 
in disease processes. Hence molecular 
markers might lead to novel therapeutic 
concepts. However, until a potential inter-
vention is achieved, any molecular predic-
tion appears as inexorable as destiny. 
 One example of a currently inevitable 
destiny in medicine is chronic allograft  
failure. Most renal allograft s have an ines-
capable fate of interstitial fibrosis and 
tubular atrophy accompanied by progres-
sive loss of allograft  function. 1 Th e intro-
duction of potent immunosuppressant 
therapy did not change this course funda-
mentally. Th e burden of failing allograft s 
is growing. It leads to medical compli-
cations in the individual patient and 
challenges to the transplant physician fac-
ing a growing number of sensitized patients 
awaiting retransplantation, increasing 
organ shortage, and rising costs. 
 Allograft fibrosis may have multiple 
origins, including acute and chronic 
rejection, infection, drug toxicity, and 
progression of donor-derived diseases 
such as hypertensive damage. Many of 
these factors are directly or indirectly 
linked to alloimmunity, as evidenced by 
the fact that these processes do not occur 
in isograft s or tolerant patients. Th us it 
would be of utmost interest to identify the 
causative, damaging process as early as 
possible. In the case of a clinically acute 
rejection we are able to identify and treat 
it successfully, although oft en not without 
scarring and a permanent loss of function. 
By contrast, we can barely infl uence the 
course of histopathologically identifi able 
chronic transplant alterations, such as 
transplant glomerulopathy, glomerulo-
sclerosis, interstitial fi brosis, and tubular 
atrophy. Recent prospective studies on 
immunosuppressive treatment of sub-
clinical morphological alterations failed 
to show a benefi t. 2,3 A next logical step 
could be to look even earlier for markers 
indicating the future development of 
chronic damage in histologically normal 
allograft s. Transcriptomic analysis might 
be a promising tool to develop molecular 
classifi ers to predict future allograft  dys-
function 4 by detecting even  ‘ sub-morpho-
logical ’ alterations ( ‘ transcriptomic 
window, ’  Figure 1 ). 
 Now the group of Minnie Sarwal  (Naesens 
 et al. , 5 this issue) has taken this step by 
generating a comprehensive set of 
genome-wide expression data from allo-
graft  biopsies of a pediatric transplant 
cohort. Biopsies with chronic allograft  
damage but without obvious infl amma-
tory alteration showed altered expression 
levels of genes known to be linked to 
immunological processes. Th e authors 
confi rmed this transcriptomic fi ngerprint 
in an independent set of protocol biopsies 
taken two years after transplantation. 
Interestingly, they could also demonstrate 
that a smaller set of transcripts, again 
mainly indicating activation of immune 
responses, were more prominently altered 
in biopsies of patients who progressed to 
histological chronic allograft  damage 18 
months later compared with individuals 
with no such progression. Th ese data from 
protocol biopsies taken 6 months aft er 
transplantation suggest a continuous 
induction of immunological processes in 
allografts prone to develop chronic 
 damage more rapidly. In transplant 
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medicine it is self-evident to compare a 
given  ‘ immune gene set ’ with transcripts 
induced in acute allograft  rejection. Hence 
this was performed as a fourth sub-project 
in the study. Clinically indicated allograft  
biopsies with acute cellular rejection and 
tubulitis showed a much more prominent 
but  ‘ functionally ’ similar expression pat-
tern compared with protocol biopsies 
with histological chronic allograft  dam-
age. Th is suggests that similar immuno-
logical processes are involved in both 
settings — that is, acute rejection and 
chronic allograft  nephropathy without 
obvious infl ammatory alterations — but 
are of a more subtle and smoldering 
nature in the latter. 
 Th e authors must be congratulated for 
this extensive study. For the identifi cation 
of marker molecules it is advantageous to 
have homogenous sample groups. How-
ever, this favors a positive outcome of such 
a marker-set definition. The authors 
applied rigorous inclusion and exclusion 
criteria for both biopsy and patient selec-
tion. Patients with delayed graft  function 
or post-transplantation complications, as 
well as biopsy samples with preexisting 
chronic damage, recurrence of disease, or 
even potential sample bias, were excluded 
from the study. Obviously this is quite dif-
ferent from the mixture of patients seen in 
routine clinical transplantation, making 
the translation of the fi ndings to a diagnos-
tic application a long journey. Despite the 
careful selection of samples, biopsies of 
 ‘ progressors ’ still showed a slightly higher 
histological chronic allograft  damage score 
(at month 6) than biopsies of  ‘ non-pro-
gressors. ’ Th is may limit to some extent the 
specifi city of the transcriptomic predictors 
but is good news for all friends of mor-
phology — as is the fact that all the end 
points of the study by Naesens  et al. 5 were 
histology-based surrogate parameters for 
chronic allograft  nephropathy and dys-
function. Hence it appears difficult to 
judge the results in a real-life perspective, 
where glomerular fi ltration rate or even 
allograft  survival is the end point of imme-
diate impact. Th e limitations of such his-
tology-based criteria in protocol biopsies 
are also highlighted by the fact that biop-
sies with the highest chronic allograft 
index had the best glomerular fi ltration 
rate (at month 6). Th is counterintuitive 
fi nding appears to be explained by the ratio 
of allograft  mass to body size of the recipi-
ent, a fi nding specifi c to pediatric trans-
plantation. 6 
 Th e study is a beautiful example of how 
sensitive screening techniques can help to 
decipher biological mechanisms involved 
in smoldering disease processes. As the 
data are now in the public domain, any-
body working in the fi eld can mine the 
data and thereby build hypotheses that are 
urgently needed to test new interventions 
designed to prevent chronic allograft 
nephropathy. Although the gene pattern 
seen in acute allograft  rejection was simi-
lar to that seen in chronic damage in this 
study, it would be an oversimplifi cation to 
conclude that intensified immuno-
suppressive therapy should be used for 
patients with normal transplant histology 
but  ‘ immune gene expression. ’ This is 
apparent in the study, as there was no cor-
relation between steroid dosage and 
degree of intrarenal immune gene expres-
sion. More importantly, two recent studies 
failed to show improvement of clinical and 
morphological outcome when immuno-
suppressive treatment was intensifi ed in 
patients with subclinical rejection identi-
fied in protocol, rather than clinically 
indicated, biopsies. 2,3 While cellular infi l-
trates are associated with the development 
of chronic allograft  dysfunction, 7,8 inten-
sifi ed routine immunosuppressive therapy 
can apparently not alter the course of this 
deleterious condition. 
 In short, the study by Naesens  et al. 5 is 
an important step toward identifying 
molecular markers for the development of 
chronic allograft  damage. However, there 
remains a long way to go to decipher the 
transcripts with predictive value for rou-
tine daily practice — let alone for the iden-
tification of therapeutic interventions. 
Until such suitable interventions are 
available, any predictive marker set may 
just indicate allograft  ’ s fate and patient ’ s 
destiny. 
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 Figure 1  |  Progression of chronic allograft damage. A  ‘ transcriptomic window, ’ as suggested by 
the study by Naesens  et al. , 5 may indicate which histologically unremarkable allografts will rapidly 
progress to morphological and functional alterations. A future therapeutic intervention should 
halt this progression or even lead to a regression of established damage (both indicated in red). 
GFR, glomerular filtration rate; IF / TA, interstitial fibrosis/tubular atrophy.  
